Urea Transporter B (UT-B) is a membrane channel protein that mediates the rapid transmembrane transport of urea and participates in urine concentration. Urea Transporter B is expressed in skin, but we found that there is little expression in human melanoma tissue. In this study, we examined the effects of UT-B overexpression in melanoma. The results indicated that there is no UT-B mRNA expression in B16 cells, and UT-B overexpression repressed B16 cell proliferation and induced apoptosis in vitro. We show that UT-B overexpression causes increased reactive oxygen species production, which may be caused by mitochondria dysfunction. The mitochondrial membrane potential (ΨΔm) was lower in UT-B-overexpressing B16 cells. The proteins involved in complexes I, III, IV and V of the respiratory chain were clearly downregulated in UT-B-overexpressing B16 cells, which would strongly reduce the activity of the electron transport chain. We found that mitochondrial release of cytochrome C into the cytoplasm also increased, indicating that apoptosis had been activated. In addition, UT-B overexpression reduced AKT phosphorylation and MDM2 expression and increased p53 expression; p53 activation may be involved in the anticancer effects of UT-B overexpression. Urea Transporter B overexpression also inhibited tumor growth in vivo. In conclusion, we demonstrated that UT-B may be related to the occurrence of melanoma and play a role in tumor development.
K E Y W O R D S
B16 cells, mitochondrial apoptosis, p53, proliferation, UT-B liver and other tissues, and has certain physiological roles in these organs. Our early experiments found that UT-B knockout mice have a mitochondrial dysfunction in the heart. 3 Mitochondria play a central and multifunctional role in malignancy progression, and control redox balance, apoptosis and oncogenic signaling. 4 Targeted mitochondrial treatment methods can regulate the development of melanoma. 5, 6 The expression of UT-B in bladder cancer was reported to be decreased and reduced further with tumor deterioration. 7 We are interested in whether there is such a phenomenon in melanoma and if UT-B can affect cancer cells through interference with mitochondrial function.
The literature has reported the expression of UT-B in the skin. 8 However, we found that UT-B expression was reduced or was absent in melanoma cell lines and melanoma tissues. This relationship suggests that UT-B may be related to the occurrence and development of melanoma. However, the mechanism by which UT-B is involved in melanoma is unclear.
TP53 is a tumor suppressor gene whose activation induces cell cycle arrest and apoptotic cell death. SIRT1 small molecule inhibitors reduce the proliferation and survival of human melanoma by activating p53. 9 Furthermore, bladder tissue of UT-B knockout mice underwent mitochondrial dysfunction and p53-dependent DNA damage and apoptosis. 10 However, there is no information on the UT-B regulatory mechanism in p53-dependent mitochondrial signaling to date.
In this study, we found that UT-B overexpression plays a role in tumor growth regulation in melanoma cell lines and mouse transplantation models, and this, combined with findings from UT-B inhibition in bladder cancer, suggests that UT-B may have tumor suppressor functions. We also analyzed the effect of UT-B on mitochondrial signaling in melanoma cells and elucidated the possible molecular mechanism. In summary, UT-B overexpression could be useful in the clinical treatment of cancer.
| MATERIAL S AND ME THODS

| Human melanoma
In this study, 4 melanoma patients were recruited from the Third 
| RT-PCR analysis
Total RNA lysate was extracted from tissue samples or cell lines using Trizol (Invitrogen, Carlsbad, CA, USA) based on standard protocols, and cDNA synthesis was performed using a Super RT Kit (BioTeke, Beijing,China)
following the manufacturer's protocol with the following primers:
UT-B forward: 5′-AATGTTCATGGCGCTCACCT-3′, and reverse:
5′-ACAAGCTGGCAATCCAACCT-3′
GAPDH primers used for the human tissues:
Forward: 5′-TGGTATCGTGGAAGGACTCATGAC-3′
Reverse: 5′-TGCCAGTGAGCTTCCCGTTCAGC-3′
GAPDH primers used for the B16 cells:
Forward: 5′-AGAAGGCTGGGGCTCATTTG-3′
Reverse: 5′-AGGGGCCATCCACAGTCTTC -3′
| MTT assay
B16 cells were inoculated in 96-well plates at a concentration of 4 × 10 3 cells/well for transfection experiments. PU14 is a novel inhibitor of human and mouse UT-B, which is effective in inhibiting UT-B activity. 11 The UT-B inhibitor PU14 group (U+ PU14) was added with 2, 4 and 6 μmol/L PU14 at the same time as transfection. After 24, 48 and 72 hours of transfection, 10 μL MTT was added and plates were incubated for 4 hours. Absorbance was measured at 570 nm using a microplate reader (FLUOstar Omega, Offenburg, Germany).
| Clonogenic capacity
Harvested cells were suspended in culture liquid and seeded in 6-well plates at a concentration of 300 cells/well. ZVAD (caspase inhibitor) was purchased from Selleckhchem. ZVAD is a caspase inhibitor that inhibits apoptosis. 12 In the experiment, 20 Forty-eight hours after B16 cells were transfected in 24-well plates, the medium was removed and the diluted DCFH-DA (10 μmol/L) was added. The cells were then incubated with DCFH-DA fluorescent probe for 20 minutes. The images were viewed and recorded with a fluorescence microscope (Olympus, Japan).
| Immunofluorescence analysis
Urea 
| Immunofluorescent staining
Sections were washed with PBS for 5 minutes and then fixed in 4% paraformaldehyde for 10 min at room temperature. All washes 
| Western blot analysis
| Isolation of the mitochondria
Mitochondrial proteins were extracted using a cell mitochondrial separation kit (Beyotime Biotechnology). B16 cells were transfected with pcDNA3.1 and pcDNA3.1-UT-B, and 5 × 10 7 cells were collected after 48 hours. Next, 1 mL of a mixture of separation reagent and PMSF (1 mmol/L) was added to 50 million cells, which were gently mixed and left in an ice bath for 10-15 minutes. The cell suspension was transferred to a suitable sized glass homogenizer and homogenized. Then, 2 μL of the cell homogenate was taken, and 30-50 μL trypan blue staining solution was added. After mixing, the proportion of trypan blue-stained cells was observed under a microscope. When the staining ratio reached 50%, the cells were homogenized at 600 g for 10 minutes at 4°C. The supernatant was then carefully transferred to another centrifuge tube and centrifuged at 11 000 g for 10 minutes at 4°C to precipitate cellular mitochondria.
The supernatant was then collected and centrifuged at 12 000 g for 10 minutes at 4°C to separate the mitochondrial cytoplasmic protein.
Next, 150 μL of PMSF was added to the mitochondria. After incubation on ice for 30 minutes, the lysate was centrifuged at 12 000 g for 10 minutes at 4°C to obtain mitochondrial protein.
| Oxygen consumption rate extracellular acidification rate
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) assay kits were MitoXpress Xtra and pH-Xtra assay kits, purchased from Luxcel Biosciences (Cork, Ireland ). We examined the oxygen consumption and glycolysis of transfected B16 cells according to the instructions.
| Animal experiments
Salmonella typhimurium A1-R (S. typhimurium A1-R) attenuated by leu and arg auxotrophy has been shown to target multiple types of cancer in mouse models. 13 We used the Gene Pulser Transfection Apparatus (Bio-Rad, 1652100, California, USA) to transfer plasmids into competent attenuated S. typhimurium. The instructions indicated that the electrophoretic conditions for attenuated S. typhimurium were the same as for E. coli, so we performed the test according to section 6.1 (E. coli) in the instructions. After many tests, we concluded that the optimal condition for the electrotransfer of attenuated Salmonella is 2.5 KV and 25 μF. We introduced plasmid into We measured tumor size and mouse weight every other day.
Tumor size was measured by calipers, and tumor volume was calculated using the following formula: V = (length) 2 × (width)/2.
After tumor injection for 14 days, mice were killed by intraperitoneal administration of an anesthetic drug cocktail (240 mg/kg) followed by cervical dislocation. Tumor tissue was removed for subsequent testing. Each tumor tissue was divided into 2 parts: 1 part was frozen at −80°C degrees for protein and RNA extraction, and the other part was fixed in 4% paraformaldehyde for immunofluorescent staining.
| Statistical analysis
All the presented data were confirmed in a minimum of 3 independent experiments and expressed as the mean ± SD. Statistical analyses were performed using SPSS version 17.0. One-way ANOVA followed by the Newman-Keuls test was used to compare the differences between pcDNA3.1 and pcDNA3.1-UT-B. P < .05 was considered to indicate a statistically significant difference.
| RE SULTS
| Urea transporter B expression in human melanoma tissue
To investigate the differences in UT-B expression in skin tumors, we obtained cancer tissue from 4 melanoma patients. Melanoma tissue was lysed, and extracts were subjected to RT-PCR. Three samples did not express UT-B ( Figure 1A) , and immunostaining of normal human skin and patients' melanoma tissue showed that UT-B was expressed in the normal skin, while UT-B expression was weak in tumors ( Figure 1B ). The expression of UT-B has been reported in the skin, 8 inferring that UT-B levels may be related to the development of melanoma. Thus, the next step was to study whether UT-B has an effect on melanoma. assay. E, Colonies generated after 10 days of incubation in methylcellulose-based medium. F, Graphs with quantitative data for the colony formation assay, respectively. G, The MTT assay detects the effect of the UT-B inhibitor PU14 on overexpression of UT-B cells. *P < .05, **P < .01 vs pcDNA3.1 group or U+PU14 group were subjected to RT-PCR and western blot analysis. As shown in Figure 2A ,B, the mRNA and protein levels of UT-B in B16 cells were 
| Urea
Overexpression of UT-B with the addition of UT-B inhibitors can
attenuate UT-B-induced apoptosis to some extent ( Figure 2G ).
Overexpression of UT-B may cause irreversible damage to the cells, so the addition of the inhibitor did not completely rescue cell survival, which may also be related to the fact that the inhibitor does not completely inhibit UT-B function. These data, together with the results from Figure 2 , suggested that UT-B plays an inhibitory role in cell proliferation and clonogenic capacity of B16 cells.
| Urea transporter B overexpression induced B16 cell apoptosis
To investigate the mechanism of UT-B overexpression in B16 cells, 10 μm. n = 3, *P < .05 vs pcDNA3.1 group or U+ZVAD group numbers were increased ( Figure 3A,B) . Meanwhile, western blotting showed that the expression of apoptotic proteins cleaved caspase-3
and BAX was increased, and the expression of BCL-2 was decreased ( Figure 3C,D) . Hoechst staining showed that after transfection with pcDNA3.1-UT-B, the number of cells undergoing apoptosis was increased ( Figure 3E,F) . In Figure 3E , the red arrow points to the apop- 
| Urea transporter B overexpression increased intracellular reactive oxygen species and reduced mitochondrial membrane potential in B16 cells
Reactive oxygen species accumulation of cells induces cytotoxicity, so we next investigated whether intracellular ROS changes following UT-B overexpression. Using flow cytometry to detect DCFH-DA fluorescent probe, we demonstrated that ROS was significantly increased following transfection with pcDNA3.1-UT-B compared with the control group ( Figure 4A,B) . ROS fluorescence assay also showed an increase in ROS production after overexpression of UT-B in B16 cells ( Figure 4E ). We examined mitochondrial membrane potential using JC-1, a mitochondria-specific fluorescent probe that exhibits potential-dependent accumulation in mitochondria with a concomitant shift in the peak of emission spectrum from green (≈529 nm) to red (≈590 nm). At the same time, mitochondrial membrane potential was found to be reduced ( Figure 4C,D) . A preliminary explanation is that mitochondrial function was decreased after transfection with pcDNA3.1-UT-B.
| Urea transporter B overexpression attenuated mitochondrial function and affected the metabolism
Mitochondrial dysfunction plays an important role in carcinogenesis and the effects of downstream pro-apoptotic proteins. 14 in the intrinsic pathway of apoptosis. 16 Figure 3 shows that after transfection with pcDNA3.1-UT-B, the expression of BCL-2 protein was decreased and the expression of BAX protein was increased.
In addition, the results showed that the expression of CYC1 cytoplasmic protein was increased ( Figure 5D,F) , indicating that the mitochondrial membrane potential may be reduced. These results suggest that the release of CYC1 from the mitochondria to the cytoplasm after transfection with pcDNA3.1-UT-B initiates the mitochondrial apoptotic pathway to induce cell death. To determine mitochondrial function, we examined the mitochondrial OCR and found that it was significantly decreased in B16 cells transfected with pcDNA3.1-UT-B (Figure 5G ), further confirming mitochondrial dysfunction. In B16 cells, after overexpression of UT-B, the expression of the glucose transporter GLUT1 was decreased and glucose uptake was reduced ( Figure 5I ,J,K). Decreased OCR indicates a decrease in oxygen consumption and a decrease in aerobic respiration ( Figure 5G ). ECAR decreased ( Figure 5H ), indicating that lactic acid production was reduced and glycolysis was weakened. The expression of the mRNA of the fat synthesis key FASN and SREBP1 is reduced ( Figure 5L ). In conclusion, overexpression of UT-B in B16 cells F I G U R E 5 Mitochondrial protein changes in transfected B16 cells. A, NDUFV1, CYC1, COX7C and ATP5F1 were reduced in the transfected B16 cell mitochondria. C, Enzymes that scavenge reactive oxygen species (SOD2) and important functional proteins (HSP60) in the mitochondria were downregulated in the mitochondria of the transfected B16 cells. D, CYC1 was upregulated in the cytoplasm of the transfected B16 cells. B, E, F, Densitometric analysis of the protein bands. G, Oxygen consumption rate decreased after transfection with pcDNA3.1-UT-B. H, Extracellular acidification rate decreased after transfection with pcDNA3.1-UT-B. I, J, GLUT1 protein levels were determined by western blot analysis. K, The amount of glucose uptake in the cells is reduced. L, RT-PCR experiments showed decreased expression of fat synthase FASN and SREBP1. *P < .05, **P < .01 vs pcDNA3.1 group affects cell metabolism. The above metabolic processes are carried out in mitochondria, and the effect of expressing UT-B on metabolism must be achieved by affecting the enzyme or protein function in the mitochondria. Conversely, these metabolic changes can also affect the function of mitochondria.
| Urea transporter B overexpression induced apoptosis through the p53 pathway
Studies show that many anti-cancer drugs can induce apoptosis in cancer cells through a variety of pathways, partly through the activation of p53. [17] [18] [19] We examined whether apoptosis of B16 cells transfected with pcDNA3.1-UT-B is associated with p53. Activated AKT enhances MDM2-mediated ubiquitination and p53 degradation. 20 We detected increased p53 expression in B16 cells transfected with pcDNA3.1-UT-B ( Figure 6 ). Furthermore, we found that upstream P-AKT and MDM2 expression was decreased, and downstream p21 expression was increased ( Figure 6 ). Therefore, transfection with pcDNA3.1-UT-B may result in p53 activation to promote apoptosis.
| Urea transporter B overexpression inhibited B16 tumor growth in vivo
To further study the effect of UT-B on B16 cells, we conducted an in vivo experiment. B16 xenograft mouse models were then used to determine the function of UT-B in vivo. We found that UT-B was expressed in mouse skin but not in the PQ group tumors ( Figure 7A ). 
| D ISCUSS I ON
To date, limited studies have shown that UT-B expression in bladder urothelial carcinoma cells is reduced or absent and that its expression is closely related to tumor grade and pathology. Low UT-B expression may be associated with the incidence, progression and aggressiveness of bladder urothelial carcinoma. 7 Urea transporter B is expressed in normal skin, 8 but we found that it was absent in B16 melanoma cells. Therefore, we hypothesized that UT-B expression may be associated with melanoma progression.
To study the role of the UT-B in the development and progression of melanoma, we overexpressed UT-B in BI6 cells. After transfection with pcDNA3.1-UT-B, the proliferation, migration and clonogenic capacity of B16 cells were decreased and apoptosis was increased.
Urea transporter B is a membrane channel protein that is in- After transfection with pcDNA3.1-UT-B, the mitochondrial membrane potential of B16 cells was also decreased, revealing mitochondrial dysfunction in these cells. The expression of NDUFV1, CYC1, COX7C and ATP5F1, which represent mitochondrial complexes I, III, IV and V, respectively, is decreased, and OCR was decreased, further indicating that mitochondrial function was impaired. In cardiac F I G U R E 6 Changes in P-AKT/p53 protein levels after transfection with pcDNA3.1-UT-B. A, AKT, P-AKT, p53, MDM2 and p21 protein levels were determined by western blot analysis. B, Densitometric analysis of protein bands. *P < .05 vs pcDNA3.1 group myocytes, the absence of UT-B could cause mitochondrial dysfunction. 3 Taking these results together, we suggest that moderate UT-B expression is an important condition for cells to maintain mitochondrial function.
Various ROS are harmful byproducts of mitochondrial respiration. The formation of mitochondrial ROS is an important component of cell metabolism and plays an important role in cell physiology. MDM2 binds to p53, preventing it from participating in transcription and inducing its degradation. 27, 28 Some groups have begun to develop small molecules that can specifically regulate p53 activity.
Small molecule inhibitors such as the analogs of MI-219 and Nutlin-3 inhibit the interaction of MDM2 and p53, releasing wild-type p53
and inducing apoptosis in cancer cells. 29 Our results show that after transfection with pcDNA3.1-UT-B, MDM2 expression was reduced and downstream p21 expression was increased, confirming the activation of p53. In addition, activation of AKT promotes nuclear entry of MDM2, decreases cellular levels of p53, and decreases p53 transcriptional activity, promoting cell survival and cell cycle progression. 30 We detected a decrease in p-AKT expression, further confirming p53 activation after transfection with pcDNA3.1-UT-B.
It has been reported that p53 translocates to the mitochondria and binds to BCL-2 or BCL-XL, thereby allowing BAX to dissociate and oligomerize 31, 32 and translocate to the mitochondrial outer membrane. It then causes mitochondrial outer membrane permeabilization, releasing cytochrome C and inducing apoptosis. 33, 34 In this study, after transfection of B16 cells with pcDNA3.1-UT-B, cytochrome C was released from mitochondria; downregulated BCL-2 and upregulated BAX levels were related to melanoma cell apoptosis, p53 is an important guardian of the genome; its expression is induced by chemical or radiation exposure and other stress conditions. 35 Chowdhury et al reported that mitochondrial functional defects induced TP53 gene expression when HCT colon cancer cells were treated with respiratory inhibitors. 36 In this experiment, mitochondrial damage induced by overexpression of UT-B may be a result of p53 activation. However, the mechanism by which UT-B overexpression in a UT-B-absent melanoma cell line induces mitochondrial dysfunction and apoptosis requires further study.
This is the first known report to date to describe the role of UT-B protein in skin. We have confirmed the role of UT-B in the development of skin melanoma, and how changes in UT-B function may seriously affect the long-term health of skin. These studies not only contribute to our understanding of skin lesion development but may also improve knowledge of other cancer types. Further research is needed to elucidate the physiological role and mechanism of UT-B in human skin.
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